Tazemetostat in Follicular Lymphoma: What Patients Need to Know After the Recent Market Withdrawal
On 9th March came the announcement that tazemetostat (Tazverik) is being voluntarily withdrawn worldwide. Ipsen, the company that markets tazemetostat, made this decision after new safety findings emerged from the ongoing SYMPHONY 1 clinical trial, which indicated a possible increased risk of secondary blood cancers when the drug was used in a specific combination regimen (lenalidomide and rituximab, also referred to as R2).
Epcoritamab Approved for Relapsed or Refractory Follicular Lymphoma on the NHS in England, Wales and Northern Ireland
NICE has approved epcoritamab (Tepkinly) on the NHS for adults in England, Wales and Northern Ireland with relapsed or refractory follicular lymphoma after two prior treatments. The decision introduces a new bispecific antibody therapy option for patients with limited treatment choices.
Follicular Lymphoma Conclave Brings Global Experts Together to Accelerate Progress Towards a Cure
In February 2026, the Follicular Lymphoma Foundation and the Josep Carreras Leukaemia Research Institute convened a global Scientific Conclave in Barcelona to confront the barriers slowing progress toward cures for follicular lymphoma. Over three days, leading experts aligned around clear priorities and a coordinated strategy designed to turn insight into decisive action for patients.
2025 Impact Round-Up: Turning Belief into Progress for Follicular Lymphoma
In 2025 the FLF accelerated scientific momentum, strengthened global collaboration, and elevated the patient voice. In her first year as Global CEO, Emma France reflects on the turning points that pushed progress from possibility into action and shares how the FL community is shaping a future where cures become achievable.
Updates from the 2025 American Society of Hematology (ASH) Annual Meeting
The Follicular Lymphoma Foundation at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, one of the world’s premier gatherings for groundbreaking hematology research.
Epcoritamab-bysp in Combination with Rituximab and Lenalidomide Approved as Treatment Option for Relapsed or Refractory Follicular Lymphoma in the U.S.
On November 18, 2025, the FDA approved epcoritamab-bysp (EPKINLY®) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma after at least one prior therapy. This approval applies to patients in the United States..
Unlock the Cure Gala 2025 Raises Funds for Vital Research
The Unlock the Cure Gala 2025 brought supporters together to fund vital research and deliver hope for people living with follicular lymphoma.
FLF shines a spotlight on follicular lymphoma at 18-ICML
We are thrilled to announce that the FLF will be taking centre stage at the upcoming 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, from June 17th-21st, 2025.
Two new ASPIRE awards target Biomarker Discovery in Follicular Lymphoma
The Mark Foundation for Cancer Research and the Follicular Lymphoma Foundation have joined forces to co-fund two new ASPIRE Awards focused on developing more personalized treatment strategies for FL.
Welcoming Emma France as FLF’s New Global CEO
The FLF welcomes Emma France as our new Global CEO. With over 20 years of non-profit leadership, Emma will help drive our mission forward with bold action and impactful change.